

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 January 2002 (17.01.2002)

PCT

(10) International Publication Number
WO 02/03959 A1

(51) International Patent Classification⁷: **A61K 9/127**

Newton, MA 02459 (US). JAIN, Rakesh, K. [US]; 65
East India Row, #14B, Boston, MA 02110 (US).

(21) International Application Number: **PCT/US01/21183**

(74) Agent: **FRASER, Janis, K.**; Fish & Richardson P.C., 225
Franklin Street, Boston, MA 02110-2804 (US).

(22) International Filing Date: **5 July 2001 (05.07.2001)**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/216,173 **6 July 2000 (06.07.2000)** US

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:

US **60/216,173 (CON)**
Filed on **6 July 2000 (06.07.2000)**

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (*for all designated States except US*): **THE
GENERAL HOSPITAL CORPORATION [US/US]; 55
Fruit Street, Boston, MA 02114 (US).**

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **CAMPBELL,
Robert, B. [US]; Apartment D9, 70 Fairlawn Avenue,
Boston, MA (US). BROWN, Edward, B. [US]; Apartment
3, 21 Woodbridge Street, Cambridge, MA 02140
(US). FUKUMURA, Dai [US]; 197 Wiswall Road,**



A1

(54) Title: DRUG DELIVERY FORMULATIONS AND TARGETING

(57) Abstract: The invention is based on the discovery that angiogenic vessels have heterogenous surface charge and that cationic liposomes actually target human tumor blood vessels only in irregularly shaped patches. The invention thus features methods for delivering therapeutic compounds to angiogenic vascular endothelial surfaces using a mixture, or "cocktail", of positively charged and neutral liposomes. The new methods can be used to target multiple regions on the same tumor vessel and/or clusters of vessels within the same tumor. Liposomes with different chemical and/or physical properties (e.g., charge, stability, solubility, diameter) can be delivered simultaneously, and can target tumor vessels and other angiogenic vessels with greater efficiency compared to cationic liposomes alone.

WO 02/03959 A1

Drug Delivery Formulations and Targeting

FIELD OF THE INVENTION

The invention relates to drug delivery.

BACKGROUND OF THE INVENTION

The efficiency of drug transport to solid tumors can vary as a function of host
5 microenvironment, tumor type, and growth. Several barriers have been shown to impede
delivery of therapeutics to solid tumors in clinically relevant concentrations (Jain, *Scientific
American*, 271(1):58-65, 1994). These barriers include a heterogeneous blood supply,
elevated tumor interstitial pressure (Jain, *Nature Medicine*, 6:655-657, 1998), and a dynamic
range of tumor blood vessel pore sizes (Hobbs et al., *Proc. Natl. Acad. Sci. USA*, 95:4607-
10 4612, 1998). Delivery of drugs to solid tumors can thus present a formidable challenge.

Studies have shown anatomical and morphological differences between normal and
tumor blood vessels (Baldwin et al., *Microvascular Research*, 42:160-178, 1991). Most
tumors are angiogenesis-dependent (Folkman, *Journal of the National Cancer Institute*,
15 82(1):4-6, 1989), requiring the development of new blood vessels. The glycoprotein layer of
the vascular endothelium of angiogenic blood vessels is composed primarily of negatively
charged functional groups (Baldwin et al., *Microvascular Research*, 42:160-178, 1991).
These functional groups can facilitate molecular interactions with positively charged
macromolecules (Delian et al., *British Journal of Cancer*, 82:1513-1518, 2000).

Accordingly, it was hypothesized that cationic liposomes could be used to target tumor
20 vessels where established glycoprotein layers had formed. Indeed, it was found that cationic
liposomes are taken up by tumor vessels to a greater extent than by the normal vascular
endothelia. Cationic liposomes have thus been used to target anionic endothelial cells in
tumors and chronic inflammation in mice, with some success (Thurston et al., *Journal of
Clinical Investigation* 101:1401-1413, 1998; Roberts et al., *Cancer Research* 57:765-772,
25 1997).

In addition to tumor growth, numerous other disease states are associated with
abnormal angiogenesis. Increased angiogenesis in the bones, joints, skin, liver, kidney, lung,
ear, nerves, heart, skeletal muscles, adipose tissue, peritoneum pleura, endocrine organs,
hematopoiesis, lymph, and other organs and systems, for example, is associated with tumors

include, for example, dioleoyltrimethyl-ammonium propane (DOTAP), N-[1-(2,3-dioleyloxy)-propyl]-N,N,N-trimethylammonium chloride (DOTMA), dimethyldioctadecylammonium bromide (DDAB), 1,2-dimyristyloxypropyl-3-dimethylhydroxyethyl (DMRIE), dioleoyl-3-dimethylammonium propane (DODAP), N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), or N-(1-(2,3-dioleyloxy)propyl)-N-(2-(sperminecarboxamido)ethyl)-N,N-dimethyl ammonium trifluoroacetate (DOSPA), or any other natural or synthetic cationic lipids. The neutral liposomes can include, for example, dioleoylphosphatidyl-choline (DOPC), dipalmitoylphosphatidylcholine (DPPC), disteroylphosphatidylcholine (DSPC), dimyristoylphosphatidylcholine (DMPC), or 1,2-sn-dioleoylphosphatidylcholine (DOPE), or any other natural or synthetic electrostatically neutral lipids.

The invention also features several methods of administering a drug to a patient. One method includes the steps of providing a formulation as described above (i.e., where at least one of the first and second therapeutic agents includes the drug to be administered), and administering the formulation to the patient (e.g., intravenously or intraarterially or by any other suitable route). The patient can be, for example, a patient suspected of having a tumor. The patient can be, for example, a mammal such as a human, a mouse, a rat, a sheep, a goat, a dog, a cat, a pig, a cow, or other animal used for research, human companionship, agriculture, or consumption. Another method includes administering to the patient a formulation that includes a heterogeneously charged drug delivery system that can include liposomes or other drug carriers. A third method includes administering to the patient two differently charged therapeutic formulations, either or both of which can include the drug.

The invention provides several advantages. Liposome formulations can function as vascular targeting systems. Several reasons currently exist for applying vascular targeting strategies. First, damage to even a single vessel can leaves hundreds or thousands of neoplastic cells starving for nutrients, resulting in the death of a significant number of malignant cells. The blood vessels carry nutrients to the cells; without the nutrients, the cells cannot survive. Second, the physical barriers that impede delivery of drugs to solid tumors do not provide an obstacle to drug delivery to the vascular endothelium. The new methods are also not limited to delivery of therapeutics to tumor interstitial space where the majority of tumor cells reside. Additionally, the vascular targeting agent can target both the tumor

vascular endothelium and a percentage of tumor cells in the tumor interstitium, resulting in additional gains in therapy. Third, endothelial cells are generally non-malignant, although they can in some cases mutate as a tumor progresses. As a result, mutant phenotypes are rare, and drug resistance is unlikely to arise.

5 Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references
10 mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

15

DETAILED DESCRIPTION

The new formulations and methods provide improved vascular targeting of drugs to solid tumors. Liposomes that include PEG lipids conjugated to phospholipid surfaces can enhance systemic circulation, reduce side effects (e.g., nausea, vomiting, headache, leukopenia), and to improve the general therapeutic dose.

20

We have discovered that the charge lining the vascular endothelium of tumor vessels is heterogeneous, and that overall vascular targeting efficiency can be improved by intravenously injecting a mixture of cationic and neutral liposomes simultaneously. We have found that this method enhances uptake of liposomes. Tumor charge heterogeneity can thus be exploited to optimally deliver therapeutics to blood vessels of solid tumors. The new
25 formulations and methods thus improve delivery of drugs, for example, to the vasculature of solid tumors and angiogenic tissue, and increase the probability of tumor cell death. Moreover, while cationic liposomes target the vascular surface, electrostatically neutral liposomes can associate with the vascular wall. Due to large tumor vascular pore sizes, they also have the ability to extravasate into tumoral tissues over time. Hence, although the

normal vasculature may take up some of the drug carried by the neutral liposomes, the total accumulation in tumors is still greater.

Liposome formulations

5 The new formulations generally include both cationic liposomes and electrostatically neutral liposomes.

The ratio of cationic liposomes to neutral liposomes will depend on the desired overall percent charge. The optimal percent charge for a particular tumor type can be determined by preparing a series of formulations with different percent charges (e.g., from 10 0% to about 50%), then determining which formulation best targets the tumor vasculature. Targeting can be quantified by intravital microscopy of cationic liposomes at the tumor vascular surface *in vivo*, according to the methods used in Fan Yuan et al. (*Cancer Research*, 54:3352-3356, 1994) to study microvascular permeability and interstitial penetration of sterically stabilized ("stealth") liposomes in a human tumor xenograft.

15 The half-life of the new liposome formulations in blood varies as a function of percent charge. Plasma clearance curves associated with the new formulations indicate that high percent charge liposomal formulations clear faster than lower percent charged formulations do. Optionally, circulation times be extended by temporarily blocking the reticuloendothelial system (RES), which can function to eliminate liposomes from systemic 20 circulation.

In general, the liposomes are prepared as follows: A desired phospholipid composition is selected for use in making the liposomes. The selected lipids can be freeze-dried or lyophilized (e.g., to enhance lipid packing and/or eliminate trace amounts of organic 25 solvents). An optimal number of phospholipid head groups are exposed for efficient hydration in a desired buffer (e.g., 50:50 saline/distilled water, 308 mM NaCl, or 40mM Hepes; pH 7.4) to form liposomes of acceptable grade. The liposomes can be fixed to a specific size by using an extruder that contains special membranes containing fixed pore sizes (e.g., 100 nm). The cationic and neutral liposomes are then combined to yield a desired ratio (e.g., from about 1:9 to about 9:1, e.g., about 3:2 to about 2:3).

30 The neutral liposomes can be prepared, for example, from dioleoylphosphatidyl-choline (DOPC), cholesterol (CHOL), and polyethylene glycol (PEG) in various ratios (e.g.,

50:45:5). Other electrostatically neutral phospholipids (e.g., dipalmitoylphosphatidylcholine (DPPC), disteroylphosphatidylcholine (DSPC), dimyristoylphosphatidylcholine (DMPC), or 1,2-sn-dioleoylphosphatidylcholine (DOPE), or other synthetic or naturally occurring electrostatically neutral lipids) can be substituted for DOPC. These and other components
5 can be purchased, for example, from Avanti Polar Lipids, Inc. (Alabaster, Alabama).

The cationic liposomes can be prepared from DOPC, CHOL, dioleoyltrimethylammonium propane (DOTAP), and PEG in various ratios (e.g., 35:10:50:5 or 45:10:40:5), to yield a desired net positive charge (defined as mole fraction of cationic lipids divided by mole fraction of all lipids in the cationic liposome) at physiological pH (e.g., pH 7.4).
10 DOTAP has low toxicity *in vivo*, but other cationic lipids (e.g., N-[1-(2,3-dioleyloxy)-propyl]-N,N,N-trimethylammonium chloride (DOTMA), dimethyldioctadecylammonium bromide (DDAB), 1,2-dimyristyloxypropyl-3-dimethylhydroxyethyl (DMRIE), dioleoyl-3-dimethylammonium propane (DODAP), N,N-dioleyl-N,N-dimethylammonium chloride, (DODAC), N-(1-(2,3-dioleyloxy)propyl)-N-(2-(sperminecarboxamido)ethyl)-N,N-dimethyl ammonium trifluoroacetate (DOSPA), or other synthetic or naturally occurring cationic
15 lipids) can be used in its place.

The size of the liposomes can also affect selectivity. Prolonged circulation time of liposomes enhances target binding and retention of liposomes. Relatively small liposomes (e.g., 200 nm or smaller) circulate longer than large liposomes (e.g., 500 nm or larger).
20 Moreover, incorporation of polyethylene glycol derivatized with phosphatidyl ethanolamine (PEG-PE) into the formulations of the individual liposomes can prolong circulation time, possibly by providing a steric barrier that prevents close contact with other liposomes or cells. Cationic liposomes without PEG are taken up by the reticuloendothelial system (RES) at a much higher rate than PEGylated cationic liposomes are.

Drugs for Incorporation into Liposome Cocktails

Both hydrophobic and water-soluble drugs can be incorporated or encapsulated in the new formulations. Paclitaxel, a chemotherapeutic drug used to treat solid malignancies such as breast, ovarian, head, and neck cancer, for example, can be stably incorporated into a liposome cocktail. Similarly, doxorubicin can be incorporated into the new liposome cocktails to achieve better vascular targeting than that observed with standard doxorubicin/liposome preparations such as DOXIL®. Other chemotherapeutic agents such as alkylating agents (e.g., mechlorethamine hydrochloride, cyclophosphamide, ifosfamide, chlorambucil, melphalan, busulfan, thiotapec, carmustine, lomustine, streptozocin), plant alkaloids (e.g., vincristine, vinblastine, vinorelbine, docetaxel), antimetabolites (e.g., methotrexate, mercaptopurine, thioguanine, fluorouracil, cytarabine, azacitidine, fludarabine, cladribine, pentostatin), antibiotics (e.g., dactinomycin, daunorubicin, idarubicin, mitoxantrone, bleomycin, plicamycin, mitomycin), or miscellaneous agents (e.g., hydroxyurea, procarbazine, dacarbazine, cisplatin, carboplatin, asparaginase, etoposide, amsacrine, mitotane, topotecan, tretinoin) can also be incorporated into the cocktails, either alone or in combination, as can other natural or synthetic therapeutic agents such as those listed in the Merck Manual and/or the Merck Index, both of which are incorporated by reference.

Nucleic acids such as DNA can also be incorporated into the new liposome cocktails (e.g., for gene therapy applications and for delivery of immunostimulatory agents such as poly I:C). The positively charged lipids of the cationic liposomes can form an electrostatic complex with the phosphate backbone of the DNA. This interaction can facilitate delivery and uptake of DNA by cells.

25 Methods of Treatment Using Liposome Cocktails

The binding of cationic liposomes to tumor vascular endothelium is heterogeneous. The liposome formulations of the invention accordingly provide a new approach to the delivery of clinically relevant concentrations of drugs to tumors. Liposome formulations containing only cationic liposomes lack the ability to target the heterogeneous tissue as thoroughly as the new formulations do. The new formulations can also include liposomes

varying in pharmacokinetic profiles. For example, charge appears to regulate liposome plasma clearance rates.

PEGylated cationic liposomes (including 5 mol% PEG) having 10% or 20% net positive charge clear the blood at a rate much slower than that of PEGylated cationic 5 liposomes containing 40% or 50% net positive charges. Liposomes having such different plasma clearance rates can be used together to enhance therapy. In addition, electrostatically neutral liposomes have a plasma clearance kinetic profile completely different from that of charged liposomes, and thus further regulate the clearance profile of a given liposome cocktail of the invention. The combination of liposomes having different surface charges and 10 plasma clearance rates can be advantageous for cancer therapy, since one type of liposome may work immediately, while another remains in circulation, available to target the tumor at a later point in time.

Examples

15 The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.

Example 1 -- Preparation of Liposome Cocktails

Both cationic liposomes and electrostatically neutral liposomes were separately 20 prepared by dissolving each individual lipid component in chloroform to a concentration of 10 mM. Aliquots of each component were transferred to round bottom flasks using a glass syringe, to provide 35:10:50:5 and 45:10:40:5 ratios of DOPC:CHOL:DOTAP:PEG for two formulations of cationic liposomes, and a 50:45:5 ratio of DOPC:CHOL:PEG for the neutral 25 liposomes. Rhodamine-labeled phospholipids were then added so that post-injection liposome uptake could be detected. The chloroform was then evaporated with adequate ventilation under an inert gas stream, resulting in a lipid film. The flask was attached to a vacuum pump for 10 to 15 minutes, after which time the lipid film was immediately suspended in a 50:50 mixture of physiological saline and distilled water. The liposomes formed in the aqueous solution were then passed through 200 nm filters (Whatman) to 30 sterilize the preparations. Next, the formulations were passed through an Avanti microextruder with a 100 nm filter membrane (Whatman). The cationic and neutral

liposomes were then combined in a 50:50 ratio to yield the desired charge ratio. Prior to injection into tumor-bearing mice, the resulting liposome formulation was warmed to 37°C.

Example 2 -- Injection of a Liposome Cocktail

5 LS174T human colon adenocarcinoma cells and B16F10 murine melanoma cells were grown in dorsal skin fold chambers in Rag2 $-/-$ mice. *In vivo* microscopy was performed using a microscope with epi-illumination. All vessels used in permeability studies were well perfused. Fluorescently labeled PEGylated and non-PEGylated cationic liposomes (100 nm) were prepared according to the method of Yuan et al. (*Cancer Research*, 55:3752-3756, 10 1995).

Dextran (mol. wt ~ 2,000,000) labeled with the fluorescent tracer FITC (Sigma, St. Louis, MO) was used to visualize blood vessels. The FITC-dextran was injected intravenously into the tail vein of a B16F10 tumor-bearing mouse. The blood flow to the tumor vessels was confirmed to have been functional before injection of liposomes.

15 Using the same experimental conditions as in the above tracer experiment, rhodamine-labeled, PEGylated cationic liposomes with a 50% charge were injected into a B16F10 tumor-bearing mouse. Regions of high liposome uptake were observed, as well as some regions of poor liposome uptake. Not all well perfused areas of B16F10 melanoma tumor vessels showed preferential uptake of cationic liposomes, indicating, unexpectedly, 20 that the response of tumors to charge is heterogeneous. Experiments with MCAIV (a murine breast tumor) and LS174T (a human adenocarcinoma of the colon) yielded similar results.

The qualitative experiments indicated that LS174T human adenocarcinoma tumors and B16F10 melanoma tumors preferentially take up cationic liposomes, compared with past experiments with anionic and electrostatically neutral liposomes, and greater vascular targeting of B16F10 vessels (n=3) was observed at higher cationic lipid ratios (>30% DOTAP). Furthermore, vascular targeting of PEGylated cationic liposomes appeared to be a random process with some vessels targeted to a greater extent than others.

Other Embodiments

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

5

WHAT IS CLAIMED IS:

- 1 1. A formulation comprising:
2 cationic liposomes comprising a first therapeutic agent, and
3 electrostatically neutral liposomes comprising a second therapeutic agent,
4 wherein the first and second therapeutic agents can be the same or different.
- 1 2. The formulation of claim 1, wherein the ratio of cationic liposomes to neutral liposomes
2 is between 1:9 and 9:1.
- 1 3. The formulation of claim 1, wherein the ratio of cationic liposomes to neutral liposomes
2 is between 1:3 and 3:1.
- 1 4. The formulation of claim 1, wherein the ratio of cationic liposomes to neutral liposomes
2 is between 2:3 and 3:2.
- 1 5. The formulation of claim 1, wherein at least one of the first and second therapeutic agents
2 is an anti-tumor drug.
- 1 6. The formulation of claim 1, wherein at least one of the first and second therapeutic agents
2 is a nucleic acid.
- 1 7. The formulation of claim 1, wherein the cationic liposomes comprise one or more lipids
2 selected from the group consisting of dioleoyltrimethylammonium propane (DOTAP),
3 N-[1-(2,3-dioleyloxy)-propyl]-N,N,N-trimethylammonium chloride (DOTMA),
4 dimethyldioctadecylammonium bromide (DDAB), 1,2-dimyristyloxypropyl-3-
5 dimethylhydroxyethyl (DMRIE), dioleoyl-3-dimethylammonium propane (DODAP),
6 N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), and N-(1-(2,3-dioleyloxy)-
7 propyl)-N-(2-(sperminecarboxamido)ethyl)-N,N-dimethyl ammonium trifluoroacetate
8 (DOSPA).
- 1 8. The formulation of claim 1, wherein at least one of the first and second therapeutic agents
2 is selected from the group consisting of mechlorethamine hydrochloride,
3 cyclophosphamide, ifosfamide, chlorambucil, melphalan, busulfan, thiotapec, carmustine,
4 lomustine, streptozocin, other alkylating agents, vincristine, paclitaxel, vinblastine,

5 vinorelbine, docetaxel, other plant alkaloids, methotrexate, mercaptapurine, thioguanine,
6 fluorouracil, cytarabine, azacitidine, fludarabine, cladribine, pentostatin, other
7 antimetabolites, dactinomycin, daunorubicin, doxorubicin, idarubicin, mitoxantrone,
8 bleomycin, plicamycin, mitomycin, other antibiotics, hydroxyurea, procarbazine,
9 dacarbazine, cisplatin, carboplatin, asparaginase, etoposide, amsacrine, mitotane,
10 topotecan, and tretinoin.

- 1 9. The formulation of claim 1, wherein the neutral liposomes comprise one or more lipids
2 selected from the group consisting of dioleoylphosphatidyl-choline (DOPC),
3 dipalmitoylphosphatidylcholine (DPPC), distearylphosphatidylcholine (DSPC),
4 dimyristoylphosphatidylcholine (DMPC), and 1,2-sn-dioleoylphosphatidylcholine
5 (DOPE).
- 1 10. A method of administering a drug to a patient, the method comprising:
2 providing a formulation of claim 1, wherein at least one of the first and second
3 therapeutic agents comprises the drug; and
4 administering the formulation to the patient.
- 1 11. The method of claim 10, wherein the patient is suspected of having a tumor.
- 1 12. The method of claim 10, wherein the patient is a mammal.
- 1 13. The method of claim 10, wherein the patient is a human.
- 1 14. The method of claim 10, wherein the formulation is administered intraarterially or
2 intravenously.
- 1 15. A method of administering a drug to a patient, the method comprising:
2 administering to the patient a formulation comprising a heterogeneously charged drug
3 delivery system that comprises the drug.
- 1 16. The method of claim 15, wherein the patient is suspected of having a tumor.

- 1 17. A method of administering a drug to a patient, the method comprising administering to
2 the patient two differently charged therapeutic formulations, one or both of which
3 comprises the drug.

- 1 18. The method of claim 17, wherein the patient is suspected of having a tumor.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/91188

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :A61K 9/127

US CL :424/450

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/450

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4,804,539 A (GUO et al.) 14 February 1989 (14.02.89), see the entire document.	1-18
A	US 4,839,175 A (GUO et al.) 13 June 1989 (13.06.89), see the entire document.	1-18

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

20 AUGUST 2001

Date of mailing of the international search report

19 NOV 2001

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-9230

Authorized officer

RAYMOND J. HENLEY III

Telephone No. (703) 308-1935